LYVE1 Antibody, HRP conjugated

說明書

中文名稱：

LYVE1兔多克隆抗體, HRP偶聯
貨號：

CSB-PA897574EB01HU
規格：

￥880
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) LYVE1 Polyclonal antibody
Uniprot No.：

Q9Y5Y7
基因名：

LYVE1
別名：

Cell surface retention sequence-binding protein 1 antibody; CRSBP 1 antibody; CRSBP-1 antibody; CRSBP1 antibody; extracellular link domain containing 1 antibody; extracellular link domain-containing 1 antibody; Extracellular link domain-containing protein 1 antibody; HAR antibody; Hyaluronic acid receptor antibody; Lymphatic endothelium specific hyaluronan receptor antibody; lymphatic vessel endothelial hyaluronan receptor 1 antibody; Lymphatic vessel endothelial hyaluronic acid receptor 1 antibody; LYVE 1 antibody; LYVE-1 antibody; LYVE1 antibody; LYVE1_HUMAN antibody; XLKD1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Lymphatic vessel endothelial hyaluronic acid receptor 1 protein (20-238AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

HRP
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes.
基因功能參考文獻：
1. LYVE1 was up-regulated in the malignant Middle Cerebral Artery Infarction. PMID: 28828208
2. this study shows up-regulation of LYVE-1 expression in the fetal circulation of conducting and exchange villi of HIV-infected pre-eclamptics PMID: 27529307
3. Dendritic cells (DCs) docked to the basolateral surface of lymphatic vessels and transited to the lumen through hyaluronan-mediated interactions with the lymph-specific endothelial receptor LYVE-1. Targeted deletion of the gene Lyve1, antibody blockade or depletion of the DC hyaluronan coat not only delayed lymphatic trafficking of dermal DCs but also blunted their capacity to prime CD8(+) T cell responses in LNs. PMID: 28504698
4. These findings reveal binding is dependent not just on clustering but also on the biochemical properties of LYVE-1 homodimers. They also mark LYVE-1 as the first Link protein superfamily member requiring covalent homodimerization for function and suggest the interchain disulfide acts as a redox switch in vivo. PMID: 27733683
5. LYVE1 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
6. Immunostaining analyses in psoriasis skin lesions suggested that the ectodomain shedding of LYVE-1 occurred in lymphatic vessels undergoing chronic inflammation. These results indicate that the ectodomain shedding of LYVE-1 might be involved in promoting pathological lymphangiogenesis. PMID: 26966180
7. These results demonstrate the prerequisite of a critical LYVE-1 threshold density and show that hyaluronan binding may be elicited in lymphatic endothelium by surface clustering with divalent LYVE-1 mAbs. PMID: 26823460
8. We have established a novel, three-protein biomarker panel that is able to detect patients with early-stage pancreatic cancer in urine specimens:LYVE-1, REG1A, and TFF1 were selected as candidate biomarkers PMID: 26240291
9. Data (including data from studies in knockout mice) suggest LYVE1 mediates adhesion of group A Streptococci (GAS) to lymphatic vesicular endothelium via capsular hyaluronan; this appears to be critical factor for lymphatic trafficking of GAS in vivo. PMID: 26352587
10. High expression of LYVE-1 is associated with atherosclerotic arteries. PMID: 25318003
11. High LYVE expression is associated with visceral pleural invasion and lymphatic thromboembolism in non-small-cell lung cancer. PMID: 25141859
12. Data indicate that detection of lymphatic vascular invasion (LVI) can be optimized by specific D2-40 or LYVE-1 staining. PMID: 21974896
13. High-low cell surface HA content of tumor cells through the interaction with LYVE-1 leads to adhesion differences. PMID: 23717428
14. FGF2 binds to LYVE-1 with a higher affinity than any other known LYVE-1-binding molecules, such as hyaluronan or PDGF-BB. Glycosylation of LYVE-1 is important for FGF2 binding. PMID: 23264596
15. CRSBP-1-associated fibrillar structures are identical to the ER network as evidenced by the co-localization of CRSBP-1 and BiP in these cells PMID: 22673514
16. LYVE-1 may have value as predictor of outcome in neuroblastoma PMID: 22241180
17. Significant correlation between LYVE-1 and Prox-1 expression was observed in non-small cell lung cancer. Expression was also correlated with lymph node metastasis. PMID: 21500548
18. LYVE-1, VEGFR-3 and CD44 all play an important role in lymphangiogenesis, invasion and metastasis PMID: 21912471
19. these data support interdependent roles for emmprin, LYVE-1 and BCRP in chemotherapeutic resistance for PEL PMID: 21660043
20. Results suggest that LYVE-1 allows the adhesion of tumor cells through the interaction of HA on the tumor cell membrane with LYVE-1. PMID: 21291635
21. Intratumoral lymph vessel density marked by LYVE-1 in laryngeal carcinoma was significantly correlated with tumor infiltration and metastasis. PMID: 17144490
22. Data show that the density of LYVE-1/+ capillaries in skeletal muscle was observed to decrease significantly over the time course of the exercise intervention. PMID: 20863269
23. findings indicated that LYVE-1 attenuation in sinusoidal endothelium was one of the manifestations of capillarization, and was associated with hepatic disease progression PMID: 19908110
24. LYVE-1 indicates an increase of lymphangiogenesis in colorectal carcinoma. PMID: 19742347
25. A study using specific markers of endothelium (CD31) and lymphatic endothelial cells (Lyve-1, Podoplanin) shows that not only angiogenesis but also lymphangiogenesis occurs within the nodule. PMID: 20011036
26. new approach measuring lymphangiogenesis using LYVE-1, a novel, specific lymphatic marker in breast cancer tissue PMID: 11689016
27. LYVE-1 is not exclusive to the lymph vessels PMID: 11719431
28. LYVE-1 does not seem to be a reliable marker for proliferating infantile hemangiomas. PMID: 16424896
29. findings indicate (1) the importance of LYVE-1, but not CD44, in regulation of HA metabolism in the maternal-fetal interface and fetal circulation, and (2) possible dual blood and lymphatic phenotypic characteristics in fetal endothelium PMID: 16569201
30. Molecular data based on gene transcriptional profiles of a 3-gene set (GPC3, LYVE1, and survivin) allow a reliable diagnosis of early hepatocellular carcinoma. PMID: 17087938
31. analysis of inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1 PMID: 17884820
32. DC-sign+ CD163+ macrophages expressing hyaluronan receptor LYVE-1 are located within chorion villi of the placenta. PMID: 18078989
33. Presence of LYVE-1 in pancreatic islets and in some pancreatic endocrine tumors may suggest structure-function relationship of LYVE-1/lymphatic vessel in hormone synthesis and secretion. PMID: 18090227
34. LYVE-1 immunohistochemistry appeared to be a useful method for detecting lymphatics invaded by cancer cells, and detailed examination of the submucosa around the tumor may be important for predicting LN metastasis. PMID: 18181096
35. LYVE-1 expression and the lymphatic density of the muscularis propria are significantly greater than those of other layers of urothelium, including the epithelium, lamina propria, perivesical fat, and serosa PMID: 18342921
36. LYVE-1 is expressed in a reticulum cell neoplasm in an axillary lymph node. This reticulum cell sarcoma is a lymphatic sinus lining cell sarcoma which might represent another subtype of reticulum cell sarcomas. PMID: 18386053
37. The normal adult human choroid does not contain typical lymph vessels, but is endowed with a significant number of LYVE-1 positive macrophages. PMID: 18689706
38. complexity in the regulation of LYVE-1 function and raise the possibility that this receptor, like CD44, may become active after appropriate unmasking in vivo. PMID: 19033446
39. LYVE-1 immunostaining in some gastrointestinal carcinoids may support a structure-function relationship of lymphatic vessels/hyaluronan receptor for modulating synthesis and secretion of hormones and amines by carcinoid tumour cells. PMID: 19291537
40. CRSBP-1 exhibits dual ligand (CRS-containing growth regulators (v-sis gene product and insulin-like growth factor binding protein-3, IGFBP-3) and hyaluronic acid) binding activity and plays a role in autocrine regulation of cell growth. PMID: 12912978
顯示更多

收起更多
亞細胞定位：

Membrane; Single-pass type I membrane protein. Note=Localized to the plasma membrane and in vesicles near extranuclear membranes which may represent trans-Golgi network (TGN) and endosomes/prelysosomeal compartments. Undergoes ligand-dependent internalization and recycling at the cell surface.
組織特異性：

Mainly expressed in endothelial cells lining lymphatic vessels.
數據庫鏈接：

HGNC: 14687

OMIM: 605702

KEGG: hsa:10894

STRING: 9606.ENSP00000256178

UniGene: Hs.655332

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human